熱門資訊> 正文

Sensei Biotherapeutics GAAP每股收益-2.84美元

2026-08-04 19:49

Sensei Biotherapeutics, Inc.(SNSE) 0

Sensei Biotherapeutics press release (FTH): Q2 GAAP EPS of -$2.84.
Cash, cash equivalents and marketable securities increased to $186.4M as of June 30, 2026, from $21.2M at Dec. 31, 2025.
R&D expenses rose to $9.2M from $2.5M, driven by PIKTOR clinical trial, manufacturing and personnel costs, partly offset by lower SNS-101 trial costs.
G&A expenses increased to $9.2M from $2.7M, mainly due to higher personnel costs and professional fees related to financing and reporting.

More on Sensei Biotherapeutics

Most and least shorted healthcare stocks with market cap up to $2B at the end of May
Seeking Alpha’s Quant Rating on Sensei Biotherapeutics
Historical earnings data for Sensei Biotherapeutics
Financial information for Sensei Biotherapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。